LifeScan has formed a transformational partnership with i-SENS to launch a continuous glucose monitoring (CGM) system under the OneTouch Vita brand. The CGM products will be sold in Germany, Ireland, Portugal, and Belgium by early 2027, with additional markets phased in over time.

“LifeScan has served the diabetes community for more than 40 years, and the addition of CGM is a significant milestone in the company’s evolution,” LifeScan Chief Financial Officer James Rushing said. “This partnership allows us to bring a CGM solution to market under the OneTouch Vita brand with the quality, reliability, and customer experience people expect from LifeScan. We are excited to begin this launch in Europe and continue to expand access in the years to come.”

With a shared focus on delivering solutions for patients living with diabetes, this collaboration will bring together LifeScan’s OneTouch brand and global distribution network with i-SENS advanced technology and manufacturing capacities. There are no changes across the rest of the OneTouch portfolio in connection with this announcement.

“Launching a CGM product line has been a long-term goal for LifeScan and we are proud to take this important step toward realizing that ambition,” LifeScan Executive Chairman Michael Hooks stated. “For years, we have seen the opportunity to incorporate CGM as a component of our offerings, and this partnership enables us to do so with a partner that shares our commitment to R&D excellence and product quality.”

LifeScan develops glucose monitoring and digital health technology. More than 20 million people and their caregivers worldwide use LifeScan’s OneTouch brand products to manage their diabetes. Together, LifeScan and OneTouch aim to improve the quality of life for people with diabetes through products and digital platforms defined by simplicity, accuracy, and trust.

i-SENS is a global in-vitro diagnostics company that researches, develops, and produces products to support human health by leveraging advanced biosensor and electrochemical technologies. With many years of experience in technology development, along with patents and research capabilities, i-SENS develops and launches pioneering, easy-to-use products. i-SENS blood glucose monitoring devices have been welcomed by customers in more than 110 countries, including Korea, the United States, and across Europe.